AI-Powered Biochip Detects Genetic Markers in 20 Minutes

Key Takeaways

• Detects multiple microRNAs in 20 minutes without amplification
• AI‑driven image analysis yields >99% identification accuracy
• Nanocavity design amplifies fluorescence from single RNA molecules
• Prototype integrates smartphone app for point‑of‑care use
• Enables large‑scale, non‑invasive disease screening

Pulse Analysis

The convergence of nanophotonics and artificial intelligence is reshaping molecular diagnostics, and NTU’s new biochip exemplifies that shift. By embedding a nanocavity—essentially a microscopic light‑trapping cavity—into a silicon chip, the device magnifies the fluorescent signal emitted when a target microRNA binds its probe. This physical amplification, combined with a deep‑learning model (Mask R‑CNN) that instantly parses the resulting image, allows the system to quantify individual RNA molecules across thousands of sites in a single frame. The result is a rapid, multiplexed assay that sidesteps the labor‑intensive PCR workflow.

Speed and sensitivity are the twin pillars of clinical relevance, and this platform delivers on both. Traditional PCR can take several hours and requires multiple amplification steps, whereas the NTU chip produces results in roughly 20 minutes with detection limits down to a few molecules per sample. Such performance opens the door to point‑of‑care testing for conditions where microRNA signatures are early indicators, including lung cancer, cardiovascular disease, and viral infections. Clinicians could obtain actionable data during a single visit, enabling earlier interventions and more precise risk stratification.

From a commercial perspective, the technology aligns with growing demand for decentralized diagnostics and AI‑enabled health tools. The integration of a smartphone‑based analysis app lowers hardware costs and simplifies deployment in resource‑limited settings. Pharmaceutical firms may also adopt the chip for high‑throughput screening of miRNA‑targeted therapeutics, accelerating drug development pipelines. Backed by Singapore’s Ministry of Education and A*STAR grants, the team is poised to pursue clinical trials and explore partnerships that could bring the device to market within the next few years, potentially reshaping the biomarker testing landscape.